RT Journal Article
SR Electronic
T1 Antibody Drug Conjugates for Cancer Therapy
JF Pharmacological Reviews
JO Pharmacol Rev
FD American Society for Pharmacology and Experimental Therapeutics
SP 3
OP 19
DO 10.1124/pr.114.009373
VO 68
IS 1
A1 Polakis, Paul
A2 Esbenshade, Timothy A.
YR 2016
UL http://pharmrev.aspetjournals.org/content/68/1/3.abstract
AB Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody. The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell. Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clinical evaluation. This review primarily covers ADCs that have advanced to clinical investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.